Diabetes
Conference Coverage
FIDELITY: Finerenone benefits patients with T2D across CKD spectrum
FIDELITY, a prespecified analysis of FIDELIO-DKD and FIGARO-DKD, showed finerenone cuts event rates in patients with normal eGFR and albuminuria...
Conference Coverage
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies...
Conference Coverage
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
News
FDA okays difelikefalin for dialysis-associated pruritus in patients with CKD
Pruritus in patients with chronic kidney disease on hemodialysis is common and has had no widely accepted go-to treatment.
Conference Coverage
Eyes on ESC ‘21: Hope for EMPEROR-Preserved, guidelines remade
But the congress will feature far more than, potentially, results the heart failure world has been longing to see and a raft of new guidelines....
From the Journals
U.S. kidney transplants grow in number and success
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
Latest News
Prevalence of youth-onset diabetes climbing, type 2 disease more so in racial/ethnic minorities
The prevalence of youth-onset diabetes in the United States rose significantly from 2001 to 2017, with rates of type 2 diabetes climbing...
Guidelines
US Preventive Services Task Force lowers diabetes screening age for overweight
From the Journals
SGLT2 inhibitor use rising in patients with DKD
From the Journals
Mediterranean diet slows progression of atherosclerosis in CHD
A Mediterranean diet is more effective in reducing atherosclerosis progression than a low-fat diet for patients with coronary heart disease, new...
News
Empagliflozin gets HFrEF approval from FDA
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...